BioXgen, a medical device company based in San Francisco, announced today an open investment offering under Regulation Crowdfunding alongside a live investor webinar scheduled for April 30, 2026, at 10:30 a.m. Pacific Time. The event will feature a demonstration of the company's cardiac patch on a heart model, providing investors and the public with a firsthand look at the technology. Company leadership, including Dr. David Skinner and Dr. John Konhilas, will discuss development progress, regulatory milestones, and the path toward first-in-human use.
Each year, more than 500,000 Americans undergo open-heart surgery, and nearly half develop postoperative atrial fibrillation (POAF) within days. POAF is the most common complication of such surgeries, yet no FDA-approved device currently exists to prevent it. BioXgen's cardiac patch aims to fill this gap by being applied directly at the surgical site. The company reports clinical data showing a tenfold reduction in postoperative AFib rates.
According to BioXgen, the device is fully developed, and the company has filed an FDA pre-submission, marking progress toward regulatory review. During the webinar, Dr. Skinner and Dr. Konhilas will present the device on a heart model, explain its application during surgery, discuss the clinical rationale, and answer live questions about the technology and investment opportunity.
“This is a chance for investors to see exactly what BioXgen has built and why we believe it could change the future of open-heart surgery,” said Dr. David Skinner, President and CEO of BioXgen. “We have moved beyond concept. The device is finished, the regulatory process is underway, and we are excited to open this next phase of growth to the community.”
The community investment round is being conducted under Regulation Crowdfunding, allowing eligible investors to participate as the company seeks FDA clearance and commercialization. The webinar is designed to provide a closer look at the device, the clinical problem it addresses, and the market opportunity for POAF prevention. Attendees can see the product, learn about company progress, and ask questions in a live interactive setting.
To learn more about the offering, visit invest.bioxgen.life. To attend the webinar, register here. BioXgen has filed a Form C with the Securities and Exchange Commission, available at invest.bioxgen.life.
